Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | HPGDS | O60760 | 7/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123966 | 0.88 | GRM5 (0.43) | SLC6A2SLC6A4SLC6A3GRM5SSTR3 | |
| SCHEMBL7113610 | 0.87 | BRAF (0.37) | SLC6A2SLC6A4SLC6A3BRAF | |
| SCHEMBL7115118 | 0.87 | CHEK2 (0.36) | SLC6A2SLC6A4SLC6A3BRAFPAK1 | |
| SCHEMBL7124402 | 0.86 | BRAF (0.40) | SLC6A4SLC6A3BRAF | |
| SCHEMBL7114457 | 0.86 | HPGDS (0.36) | SLC6A2SLC6A4SLC6A3HPGDSGRM5 | |
| SCHEMBL7116911 | 0.83 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HPGDSGRM5 | |
| SCHEMBL7114448 | 0.83 | KDR (0.41) | BRAF | |
| SCHEMBL7123339 | 0.83 | POLB (0.43) | HPGDSGRM5PAK1 | |
| SCHEMBL7125022 | 0.83 | EPHX2 (0.42) | GRM5 | |
| SCHEMBL7116858 | 0.82 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | SLC6A2 1156/4885SLC6A4 2137/4885SLC6A3 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.